公开(公告)号：US10822325B2

公开(公告)日：2020-11-03

申请号：US15735840

申请日：2016-06-10

Applicant: UNM RAINFOREST INNOVATIONS ,  ROSALIND FRANKLIN UNIVERSITY

Inventor： Tudor I. Oprea ,  Cristian George Bologa ,  Oleg Ursu ,  Jun-Yong Choe ,  Cristina Iancu

IPC: C07D317/66 ,  A61K31/36 ,  A61P3/10 ,  G16B35/00 ,  G16C20/60 ,  C07C317/36 ,  A23L33/125 ,  A61K45/06

Abstract: The present invention relates to compounds which have been discovered to be potent ligands (inhibitors) of human GLUT5 (glucose transporter type 5), a facilitative glucose transporter that transports fructose, and their use as ligands assays which can uncover additional ligands of GLUT5, having the potential for being used as drugs. In addition, the present invention is directed to compounds, chemical compositions and methods for treating disease states and conditions which are mediated through GLUT5, including such disease states and conditions as GLUT5 deficiency syndrome, diabetes (type I and II), cancer, metabolic diseases including metabolic syndrome and fatty liver disease, among others.

公开(公告)号：US10787669B2

公开(公告)日：2020-09-29

申请号：US16438015

申请日：2019-06-11

Applicant: Rosalind Franklin University of Medicine and Science ,  The McLean Hospital Corporation

Inventor： Michelle L. Hastings ,  Ole Isacson ,  Joanna A. Korecka-Roet

IPC: C07H21/02 ,  C07H21/04 ,  C12N15/113

Abstract: The present disclosure relates generally to compounds comprising oligonucleotides complementary to a Leucine-Rich-Repeat-Kinase (LRRK2) RNA transcript. Certain such compounds are useful for hybridizing to a LRRK2 RNA transcript, including but not limited to a LRRK2 RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the LRRK2 transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Parkinson's disease.

公开(公告)号：US20200216846A1

公开(公告)日：2020-07-09

申请号：US16536981

申请日：2019-08-09

Applicant: Ionis Pharmaceuticals, Inc. ,  Rosalind Franklin University of Medicine and Science

Inventor： Frank Rigo ,  Michelle L. Hastings

IPC: C12N15/113 ,  A61K31/7088

Abstract: The present invention provides compounds comprising oligonucleotides complementary to a CLN3 transcript. Certain such compounds are useful for hybridizing to a CLN3 transcript, including but not limited to a CLN3 transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the CLN3 transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Batten Disease.

公开(公告)号：US20200017560A1

公开(公告)日：2020-01-16

申请号：US16511103

申请日：2019-07-15

Applicant: Rosalind Franklin University of Medicine & Science

Inventor： Bruce L. Riser

IPC: C07K14/47 ,  A61K38/17 ,  A61K38/04 ,  A61K9/00 ,  A61K35/12 ,  A61K35/28 ,  A61K35/51 ,  A61K38/10 ,  C07K14/475

Abstract: The present invention provides a method for treating a human patient with a pathology by administering to the subject an effective amount of an agent selected from the group of: native full-length CCN3 proteins; analog CCN3 full-length proteins with native cysteine residues substituted by a replacement amino acid; CCNp native peptide fragments having from about 12 to about 20 amino acids; analog CCNp peptide fragments with native cysteine residues substituted with a replacement amino acid; and combinations thereof.

公开(公告)号：US10370667B2

公开(公告)日：2019-08-06

申请号：US15837926

申请日：2017-12-11

Applicant: Rosalind Franklin University of Medicine and Science ,  The McLean Hospital Corporation

Inventor： Michelle L. Hastings ,  Ole Isacson ,  Joanna A. Korecka-Roet

IPC: A61K48/00 ,  C07H21/02 ,  C07H21/04 ,  C12N15/113

Abstract: The present disclosure relates generally to compounds comprising oligonucleotides complementary to a Leucine-Rich-Repeat-Kinase (LRRK2) RNA transcript. Certain such compounds are useful for hybridizing to a LRRK2 RNA transcript, including but not limited to a LRRK2 RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the LRRK2 transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Parkinson's disease.

公开(公告)号：US20180233059A1

公开(公告)日：2018-08-16

申请号：US15433703

申请日：2017-02-15

Applicant: Rosalind Franklin University of Medicine and Science

Inventor： Tamzin J. Batteson ,  Sarah S. Garber

IPC: G09B9/00 ,  G09B23/30 ,  G09B7/02 ,  G09B7/10 ,  G09B19/00

CPC classification number: G09B9/00 ,  G09B7/02 ,  G09B7/10 ,  G09B19/00 ,  G09B23/30

Abstract: In one aspect, a method for improving patient outcome is disclosed. The method includes (i) observing a first interview of a simulated patient, wherein, during the first interview, the simulated patient is in a first form; (ii) participating in a second interview of the simulated patient, wherein, during the second interview, the simulated patient is in a second form, and wherein participating in the second interview comprises interacting with the simulated patient; (iii) participating in a third interview of the simulated patient, wherein, during the third interview, the simulated patient is in the first form, and wherein participating in the third interview comprises interacting with the simulated patient; and (iv) based at least in part on the first, second, and third interviews, creating a plan of care for the simulated patient.

公开(公告)号：US20180117073A1

公开(公告)日：2018-05-03

申请号：US15835698

申请日：2017-12-08

Applicant: Rosalind Franklin University of Medicine and Science

Inventor： Michelle L. Hastings

IPC: A61K31/712 ,  C12N15/113

Abstract: The present disclosure relates generally to compounds comprising oligonucleotides complementary to a cystic fibrosis transmembrane conductance regulator (CFTR) RNA transcript. Certain such compounds are useful for hybridizing to a CFTR RNA transcript, including but not limited to a CFTR RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the CFTR transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Cystic Fibrosis.

公开(公告)号：US20180052171A1

公开(公告)日：2018-02-22

申请号：US15691422

申请日：2017-08-30

Applicant: Rosalind Franklin University of Medicine & Science

Inventor： Kenneth Beaman

IPC: G01N33/68

CPC classification number: G01N33/689

Abstract: The present invention provides a kit for determining male fertility including a container system containing a plurality of enzyme-linked antibodies one of each capable of binding to analytes Atp6v0a2, G-CSF, MIP 1α, and MCP-1. The kit further includes suitable packaging and a set of instructions for using the enzyme-linked antibodies with a seminal sample to determine the fertility of the sample.

公开(公告)号：US20180022722A1

公开(公告)日：2018-01-25

申请号：US15671833

申请日：2017-08-08

Applicant: Rosalind Franklin University of Medicine and Science

Inventor： Grace E. Stutzmann ,  Russell Dahl ,  Christopher H. Kaiho

IPC: C07D307/54 ,  C07D307/52 ,  C07D407/12 ,  C07D405/12

CPC classification number: C07D307/54 ,  C07D307/52 ,  C07D405/12 ,  C07D407/12

Abstract: Disclosed herein are methods and compositions comprising compounds capable of normalizing neuronal calcium dyshomeostasis. Also disclosed are methods comprising these compounds for treating neuronal or neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, fronto-temporal dementia, Pick's disease, chronic traumatic encepholopathy, traumatic brain injury, stroke, cerebellar ataxia, multiple sclerosis, Down syndrome, and aging-related CNS disorders.

公开(公告)号：US09840710B2

公开(公告)日：2017-12-12

申请号：US15349840

申请日：2016-11-11

Applicant: Rosalind Franklin University of Medicine and Science ,  The McLean Hospital Corporation

Inventor： Michelle L. Hastings ,  Ole Isacson ,  Joanna A. Korecka-Roet

IPC: C07H21/02 ,  C07H21/04 ,  A61K48/00 ,  C12N15/113

CPC classification number: C12N15/1137 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/3231 ,  C12N2310/3233 ,  C12N2310/346 ,  C12N2320/33 ,  C12Y207/11001 ,  C12N2310/321 ,  C12N2310/3521 ,  C12N2310/3525 ,  C12N2310/322 ,  C12N2310/3533

Abstract: The present disclosure relates generally to compounds comprising oligonucleotides complementary to a Leucine-Rich-Repeat-Kinase (LRRK2) RNA transcript. Certain such compounds are useful for hybridizing to a LRRK2 RNA transcript, including but not limited to a LRRK2 RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the LRRK2 transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Parkinson's disease.